

Pan-Canadian Pharmaceutical Alliance: Active Negotiations

As of August 31, 2019

There are 47 negotiations **currently underway** for the following drug products:

Drug Product Brand Name (Generic Name)	Indication/Use
Adlyxine (lixisenatide)	Used to treat Type 2 diabetes mellitus
Blincyto (blinatumomab)	Used to treat Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL)
Bosulif (bosutinib)*	Used to treat chronic myeloid leukemia.
Brineura (cerliponase alfa)	Used to treat neuronal ceroid lipofuscinosis type 2
Cabometyx (cabozantinib)	Used to treat renal cell carcinoma
Cresemba (isavuconazole)	Used to treat invasive aspergillosis and mucormycosis
Delstrigo (doravirine/lamivudine/ tenofovir disoproxil fumarate)	Used to treat HIV infection
Dupixent (dupilumab)	Used to treat atopic dermatitis
Emerade (epinephrine bitartrate)*	Used for the emergency treatment of anaphylactic reactions
Folotyn (pralatrexate)	Used to treat peripheral T-cell lymphoma
Fulphila (pegfilgastrim)	Used to treat febrile neutropenia in non-myeloid malignancies
Herceptin SC (trastuzumab)	Used to treat breast cancers
Herzuma (trastuzumab)	Used to treat early breast cancer, metastatic breast cancer, and gastric cancer
Humira (citrate free) (adalimumab)	Used for multiple indications
Ibrance/Faslodex (palbociclib/fulvestrant)*	Used to treat advanced or metastatic breast cancer
Januvia (sitagliptin)	Used to treat Type 2 diabetes mellitus
Kanuma (sebelipase alfa)	Used to treat lysosomal acid lipase deficiency
Keytruda (pembrolizumab)	Used to treat classic Hodgkin lymphoma
Keytruda (pembrolizumab)	Used to treat metastatic urothelial carcinoma
Keytruda (pembrolizumab)*	Used to treat metastatic non-squamous non-small cell lung cancer
Kuvan (sapropterin dihydrochloride)	Used to treat Phenylketonuria (PKU)
Mavenclad (cladribine)	Used to treat relapsing-remitting multiple sclerosis
Ogivri (trastuzumab)	Used to treat early breast cancer, metastatic breast cancer, and gastric cancer
Opdivo (nivolumab)	Used for the adjuvant treatment of melanoma
Opdivo (nivolumab)	Used to treat classic Hodgkin's lymphoma
Opsumit (macitentan)	Used to treat pulmonary arterial hypertension
Orfadin Oral Suspension (nitisinone)*	Used to treat hereditary tyrosinemia type 1 (HT-1)
Pifetro (doravirine)	Used to treat HIV infection
Praluent (alirocumab)	Used for the prevention of cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD)
Prevymis (letermovir)	Used for the prevention of cytomegalovirus infection
Segluromet (ertugliflozin/metformin hydrochloride)	Used to treat Type 2 diabetes mellitus
Skyrizi (risankizumab)	Used to treat plaque psoriasis
Soliqua (lixisenatide/insulin glargine)	Used to treat Type 2 diabetes mellitus

Steglatro (ertugliflozin)	Used to treat Type 2 diabetes mellitus
Sublocade (buprenorphine)	Used to treat opioid dependence
Tagrisso (osimertinib)	Used to treat first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)
Trazimera (trastuzumab)	Used to treat early breast cancer, metastatic breast cancer, and gastric cancer
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)	Used to treat chronic obstructive pulmonary disease
Trulicity (dulaglutide)	Used to treat Type 2 diabetes mellitus
Velphoro (sucroferric oxyhydroxide)	Used to treat hyperphosphatemia in patients with end stage renal disease.
Venclexta/rituximab (venetoclax/rituximab)	Used to treat chronic lymphocytic leukemia
Vizimpro (dacomitinib)*	Used to treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR)-activating mutations
Vyzulta (latanoprostene bunod)*	Used to treat open-angle glaucoma or ocular hypertension.
Xalkori (crizotinib)*	Used to treat ROS1-positive advanced non-small cell lung cancer
Xarelto (rivaroxaban)	Used for the prevention of cardiovascular events in coronary and peripheral artery disease
Xeljanz (tofacitinib)	Used to treat ulcerative colitis
Xtandi (enzalutamide)	Used to treat high risk non-metastatic castrate resistant prostate cancer

* New drug products since last update of July 31, 2019.